Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00730522 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence
A Phase 2 study, sponsored by Catalyst Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00730522: Clinical Trial Phase 2 study, sponsored by Catalyst Pharmaceuticals.
NCT00730522 is a Phase 2 study that was terminated before completion, run by Catalyst Pharmaceuticals. The registered enrollment target is 55 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00730522, a Phase 2 study, was terminated before completion, sponsored by Catalyst Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be methamphetamine-free in the last 2 weeks of the study's Treatment Phase (Weeks 11 and 12).
Interventions
- DRUG Matching Placebo
- DRUG CPP-109 vigabatrin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Why NCT00730522 stopped before completion
NCT00730522 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT00730522 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00730522 about?
NCT00730522 is a clinical study titled "Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence". The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be methamphetamine-free in the last 2 weeks of the study's Treatment Phase (Weeks 11 and 12).
What is the current status of trial NCT00730522?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2008-07. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00730522?
The interventions under investigation include: Matching Placebo (DRUG), CPP-109 vigabatrin (DRUG).
Who is sponsoring clinical trial NCT00730522?
This trial is sponsored by Catalyst Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00730522's enrollment target sits among peer trials
55 1153rd of 2000 higher than 841 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia